Eftozanermin Alfa Biosimilar – Anti-TRAILR2 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2014; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Eftozanermin Alfa Biosimilar, also known as Anti-TRAILR2 fusion protein, is a promising therapeutic agent that has been extensively studied for its potential in cancer treatment. This biosimilar is a fusion protein that combines the sequence of the human TRAILR2 receptor with the Fc region of an antibody, making it a potent anti- cancer agent with a unique mechanism of action. In this article, we will discuss the structure, activity, and potential applications of Eftozanermin Alfa Biosimilar in detail.
Eftozanermin Alfa Biosimilar is a recombinant fusion protein consisting of two main components: the extracellular domain of the human TRAILR2 receptor and the Fc region of an antibody. The TRAILR2 domain is responsible for the anti- cancer activity of this biosimilar, while the Fc region provides stability and prolongs its half-life in the body. The TRAILR2 domain is composed of four cysteine-rich repeats, which are essential for binding to its ligand, TRAIL (TNF-related apoptosis-inducing ligand). The Fc region, on the other hand, is derived from the constant region of an antibody and is responsible for binding to Fc receptors on immune cells, thereby activating their anti-tumor activity.
cancer activity through the TRAILR2 domain, which binds to TRAIL on the surface of cancer cells. This binding triggers a signaling cascade that leads to the activation of the apoptotic pathway, resulting in cell death. Unlike traditional chemotherapeutic agents, Eftozanermin Alfa Biosimilar specifically targets cancer cells without harming normal cells, making it a promising therapeutic option with minimal side effects. Moreover, the Fc region of this biosimilar also plays a crucial role in its activity by activating immune cells, such as natural killer cells and macrophages, to destroy cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
The main therapeutic target of Eftozanermin Alfa Biosimilar is TRAILR2, a death receptor that is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer. TRAILR2 is a member of the tumor necrosis factor receptor (TNFR) superfamily and is involved in the regulation of cell death and survival. In cancer cells, TRAILR2 is often upregulated, leading to increased resistance to apoptosis and promoting tumor growth. By targeting TRAILR2, Eftozanermin Alfa Biosimilar can induce apoptosis in cancer cells, thereby inhibiting tumor growth and progression.
Eftozanermin Alfa Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. This biosimilar has the potential to be used as a monotherapy or in combination with other anti- cancer agents, such as chemotherapy and immune checkpoint inhibitors. Its unique mechanism of action and minimal side effects make it a promising therapeutic option for cancer patients who have failed conventional treatments. Moreover, Eftozanermin Alfa Biosimilar can also be used in research studies to investigate the role of TRAILR2 in cancer biology and to develop new treatment strategies targeting this receptor.
In summary, Eftozanermin Alfa Biosimilar is a fusion protein with a unique structure and mechanism of action that holds great potential in cancer treatment. Its ability to specifically target cancer cells and activate the immune system makes it a promising therapeutic option for various types of cancer. Further research and clinical trials
ProteoGenix catalogue number PX-TA2014. For research use only.
Target: Eftozanermin Alfa Biosimilar – Anti-TRAILR2 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Eftozanermin Alfa Biosimilar – Anti-TRAILR2 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
